Matching articles for "Morphine"
Issue 1665 · December 12, 2022
Opioids for Pain

A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):193-200
A new CDC guideline for prescribing opioids for pain recently became available. Nonopioid drugs for pain were reviewed in a previous issue.
Issue 1665 · December 12, 2022
Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

View the Comparison Table: Some Oral/Transdermal Opioid Analgesics

Med Lett Drugs Ther. 2022 Dec 12; 64(1665):e199-202
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Issue 1619 · March 8, 2021
Oliceridine (Olinvyk) - A New Opioid for Severe Pain

Oliceridine ( Olinvyk - Trevena), an IV opioid agonist, has been approved by the FDA for management of acute pain severe enough to require an opioid and for which alternative treatment options are inadequate.

Med Lett Drugs Ther. 2021 Mar 8; 63(1619):37-9
Oliceridine ( Olinvyk - Trevena), an IV opioid agonist, has been approved by the FDA for management of acute pain severe enough to require an opioid and for which alternative treatment options are inadequate.
Issue 1606 · September 7, 2020
Drugs for COPD

The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and…

Med Lett Drugs Ther. 2020 Sep 7; 62(1606):137-44
The main goals of treatment for chronic obstructive pulmonary disease (COPD) are to relieve symptoms, reduce the frequency and severity of exacerbations, and prevent disease progression. Several guidelines and review articles on COPD treatment have been published in recent years. Treatment of acute exacerbations is not discussed here.
Issue 1593 · March 9, 2020 Free
Addendum: Drug Interaction between Opioids and Oral P2Y12 Platelet Inhibitors

Opioids delay gastric emptying and the absorption of many oral drugs, including the P2Y 12 inhibitors clopidogrel ( Plavix , and generics), prasugrel ( Effient , and generics), and ticagrelor (Brilinta) ,…

Med Lett Drugs Ther. 2020 Mar 9; 62(1593):40
Opioids delay gastric emptying and the absorption of many oral drugs, including the P2Y 12 inhibitors clopidogrel ( Plavix , and generics), prasugrel ( Effient , and generics), and ticagrelor (Brilinta) , which are commonly used for initial treatment of acute coronary syndrome (ACS). An article in our February 25, 2019 issue reviewed studies showing that coadministration of opioids delayed and decreased absorption of oral P2Y 12 inhibitors and increased platelet reactivity. Recently published clinical outcomes data may add to these concerns.
Issue 1544 · April 9, 2018
Opioids for Pain

Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations…

Med Lett Drugs Ther. 2018 Apr 9; 60(1544):57-64
Use of nonopioid drugs for pain was reviewed in a previous issue. For many types of moderate to severe acute pain, acetaminophen and/or an NSAID may be as effective as an opioid. Immediate-release formulations of full opioid agonists should generally be used for acute pain that is severe enough to require treatment with an opioid. Use of extended-release or long-acting opioid formulations initially and treatment durations >1 week have been associated with an increased risk of unintended long-term use.
Issue 1544 · April 9, 2018
Comparison Table: Some Oral/Topical Opioid Analgesics (online only)

View the Comparison Table: Some Oral/Topical Opioid Analgesics

Med Lett Drugs Ther. 2018 Apr 9; 60(1544):e64-7
View the Comparison Table: Some Oral/Topical Opioid Analgesics
Issue 1522 · June 5, 2017
Abuse-Deterrent Opioids

Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Since our last article on this subject,…

Med Lett Drugs Ther. 2017 Jun 5; 59(1522):95-6
Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Since our last article on this subject, several new abuse-deterrent opioid formulations have been approved by the FDA, including an oxycodone tablet formulation ( Roxybond – Inspirion) that is the first immediate-release opioid product FDA-approved to include claims of abuse deterrence in its labeling. No opioid formulation prevents consumption of a large number of intact dosage units, the most common method of abuse. Abuse-deterrent formulations have one or more properties that make their intentional nontherapeutic use more difficult, less attractive, or less rewarding.
Issue 1521 · May 22, 2017
FDA Warns Against Use of Codeine and Tramadol in Children and Breastfeeding Women

The FDA has issued new warnings about the use of the opioid analgesics codeine and tramadol in children, particularly those <12 years old, and in breastfeeding women due to concerns about the risk of…

Med Lett Drugs Ther. 2017 May 22; 59(1521):86-8
The FDA has issued new warnings about the use of the opioid analgesics codeine and tramadol in children, particularly those <12 years old, and in breastfeeding women due to concerns about the risk of respiratory depression and death. The FDA previously issued warnings about these drugs in 2013 and 2015.
Issue 1519 · April 24, 2017
Arymo ER - A New Abuse-Deterrent Morphine Formulation

The FDA has approved Arymo ER (Egalet), a new extended-release, abuse-deterrent tablet formulation of morphine sulfate, for management of pain severe enough to require daily, around-the-clock, long-term opioid…

Med Lett Drugs Ther. 2017 Apr 24; 59(1519):68-9
The FDA has approved Arymo ER (Egalet), a new extended-release, abuse-deterrent tablet formulation of morphine sulfate, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Arymo ER can only be marketed to deter abuse by injection because another single-entity, extended-release morphine product, MorphaBond , which has not been marketed to date, has marketing exclusivity for deterrence of abuse by the intranasal route through October 2018.
Issue 1497 · June 20, 2016
A New Abuse-Deterrent Opioid - Xtampza ER

The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid…

Med Lett Drugs Ther. 2016 Jun 20; 58(1497):77-8
The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Issue 1489 · February 29, 2016 Free
Clarification: Half-Life of Heroin

A reader expressed concern that a statement in our article Naloxone (Narcan) Nasal Spray for Opioid Overdose (Med Lett Drugs Ther 2016; 58:1) might be misleading. We stated that heroin has a half-life of 2-6…

Med Lett Drugs Ther. 2016 Feb 29; 58(1489):32
A reader expressed concern that a statement in our article Naloxone (Narcan) Nasal Spray for Opioid Overdose (Med Lett Drugs Ther 2016; 58:1) might be misleading. We stated that heroin has a half-life of 2-6 minutes, which is correct, but heroin is a prodrug that is rapidly metabolized to 6-acetylmorphine and morphine. The risk of respiratory depression is related to those active metabolites, and it may persist well beyond the clearance of heroin from the blood.
Issue 1476 · August 31, 2015
Abuse-Deterrent Opioid Formulations

Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Three available opioid formulations,…

Med Lett Drugs Ther. 2015 Aug 31; 57(1476):119-21
Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Three available opioid formulations, OxyContin (Purdue), Embeda (Pfizer), and Hysingla ER (Purdue), now include claims of abuse deterrence in their package inserts.
Issue 1468 · May 11, 2015
Extended-Release Hydrocodone (Hysingla ER) for Pain

The FDA has approved a second extended-release (ER) formulation of the oral opioid agonist hydrocodone ( Hysingla ER – Purdue) for management of pain severe enough to require continuous long-term therapy and…

Med Lett Drugs Ther. 2015 May 11; 57(1468):71-2
The FDA has approved a second extended-release (ER) formulation of the oral opioid agonist hydrocodone ( Hysingla ER – Purdue) for management of pain severe enough to require continuous long-term therapy and for which alternative treatment options are inadequate. Hysingla ER tablets have abuse-deterrent properties to discourage their misuse.
Issue 1453 · October 13, 2014
Rescheduling of Hydrocodone Combination Products

The Drug Enforcement Administration (DEA) has reclassified all hydrocodone combination products as schedule II controlled substances; they were previously classified as schedule III. Hydrocodone alone (Zohydro…

Med Lett Drugs Ther. 2014 Oct 13; 56(1453):101-2
The Drug Enforcement Administration (DEA) has reclassified all hydrocodone combination products as schedule II controlled substances; they were previously classified as schedule III. Hydrocodone alone (Zohydro ER) is already a schedule II controlled substance.
Issue 1444 · June 9, 2014
Extended-Release Hydrocodone (Zohydro ER) for Pain

The FDA has approved an extended-release oral formulation of the opioid agonist hydrocodone ( Zohydro ER – Zogenix) for management of pain severe enough to require continuous, long-term therapy and for which…

Med Lett Drugs Ther. 2014 Jun 9; 56(1444):45
The FDA has approved an extended-release oral formulation of the opioid agonist hydrocodone ( Zohydro ER – Zogenix) for management of pain severe enough to require continuous, long-term therapy and for which alternative treatment options are inadequate. Zohydro ER is the first single-ingredient hydrocodone product to be marketed in the US. Hydrocodone has been available for years in combination with acetaminophen ( Vicodin , and others) or ibuprofen ( Vicoprofen , and others).
Issue 128 · April 1, 2013
Drugs for Pain

Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less…

Treat Guidel Med Lett. 2013 Apr; 11(128):31-42
Pain can be acute or chronic. The two major types of chronic pain are nociceptive pain and neuropathic pain. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids and is often treated with adjuvant drugs such as antidepressants and antiepileptics. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1390 · May 14, 2012
Fentanyl Sublingual Spray (Subsys) for Breakthrough Cancer Pain

The FDA has approved a sublingual spray formulation of fentanyl ( Subsys – Insys) for management of breakthrough pain in adult cancer patients who are receiving and are tolerant to opioid therapy (taking…

Med Lett Drugs Ther. 2012 May 14; 54(1390):39-40
The FDA has approved a sublingual spray formulation of fentanyl ( Subsys – Insys) for management of breakthrough pain in adult cancer patients who are receiving and are tolerant to opioid therapy (taking ≥60 mg/day of oral morphine or the equivalent). Fentanyl is already available in the US for intravenous, intrathecal, epidural, transdermal and transmucosal use.
Issue 1390 · May 14, 2012
Off-Label Use of Ketorolac for Athletic Injuries

Recent reports indicate that intramuscular (IM) injection of the nonsteroidal anti-inflammatory drug (NSAID) ketorolac ( Toradol , and others), sometimes directly into injured muscles, has become a common…

Med Lett Drugs Ther. 2012 May 14; 54(1390):37
Recent reports indicate that intramuscular (IM) injection of the nonsteroidal anti-inflammatory drug (NSAID) ketorolac ( Toradol , and others), sometimes directly into injured muscles, has become a common practice in US locker rooms.
Issue 92 · April 1, 2010
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is…

Treat Guidel Med Lett. 2010 Apr; 8(92):25-34
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain can be treated with nonopioid analgesics or opioids. Neuropathic pain is less responsive to opioids; adjuvant medicines such as antidepressants and anticonvulsants are often used to treat neuropathic pain. Combining different types of analgesics may provide an additive analgesic effect without increasing adverse effects.
Issue 1334 · March 22, 2010
A Morphine/Naltrexone Combination (Embeda) for Pain

The FDA has approved an agonist/antagonist combination of morphine and naltrexone ( Embeda – King) for treatment of chronic moderate to severe pain requiring around-the-clock analgesia for an extended period…

Med Lett Drugs Ther. 2010 Mar 22; 52(1334):22-3
The FDA has approved an agonist/antagonist combination of morphine and naltrexone ( Embeda – King) for treatment of chronic moderate to severe pain requiring around-the-clock analgesia for an extended period of time. The addition of naltrexone is intended to prevent abuse of morphine.
Issue 1318 · August 10, 2009
Tapentadol (Nucynta) - A New Analgesic

The FDA has approved tapentadol hydrochloride (Nucynta - Ortho-McNeil Janssen) for oral treatment of moderate to severe acute pain in patients ≥18 years old. It has been classified as a Schedule II…

Med Lett Drugs Ther. 2009 Aug 10; 51(1318):61-2
The FDA has approved tapentadol hydrochloride (Nucynta - Ortho-McNeil Janssen) for oral treatment of moderate to severe acute pain in patients ≥18 years old. It has been classified as a Schedule II controlled substance
Issue 1270 · September 24, 2007
Fentanyl Buccal Tablet (Fentora) for Breakthrough Pain

The FDA has approved a transmucosal tablet formulation of fentanyl citrate ( Fentora - Cephalon) for management of breakthrough pain in opioid-tolerant patients with cancer. An oral transmucosal fentanyl…

Med Lett Drugs Ther. 2007 Sep 24; 49(1270):79-6
The FDA has approved a transmucosal tablet formulation of fentanyl citrate ( Fentora - Cephalon) for management of breakthrough pain in opioid-tolerant patients with cancer. An oral transmucosal fentanyl lozenge on a stick ( Actiq , and others) is also available for this indication, and is widely used off-label for chronic, non-cancer pain as well.
Issue 56 · April 1, 2007
Drugs for Pain

Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants…

Treat Guidel Med Lett. 2007 Apr; 5(56):23-32
Pain can be acute or chronic. Chronic pain has been broadly classified into two types: nociceptive and neuropathic. Nociceptive pain is generally treated with nonopioid analgesics and opioids. Antidepressants and anticonvulsants have been used to treat neuropathic pain. Combining two different types of analgesics may nprovide an additive analgesic effect without increasing adverse effects.
Issue 1251 · January 1, 2007
Oral Oxymorphone (Opana)

Oxymorphone hydrochloride, a semi-synthetic opioid agonist, has been available for many years in the US as Numorphan (Endo) for parenteral use and as a rectal suppository. Now it has been approved by the FDA…

Med Lett Drugs Ther. 2007 Jan 1; 49(1251):3-4
Oxymorphone hydrochloride, a semi-synthetic opioid agonist, has been available for many years in the US as Numorphan (Endo) for parenteral use and as a rectal suppository. Now it has been approved by the FDA for oral administration as an immediate-release (IR) tablet (Opana) for treatment of moderate to severe acute pain, and as an extended-release tablet (Opana ER) for treatment of moderate to severe pain in patients requiring continuous opioid treatment for an extended period of time.
Issue 1223 · December 5, 2005
Ziconotide (Prialt) for Chronic Pain

The FDA has approved ziconotide ( Prialt - Elan) intrathecal infusion for management of severe chronic pain in patients who are intolerant of or refractory to other treatments. Ziconotide is a synthetic…

Med Lett Drugs Ther. 2005 Dec 5; 47(1223):103-4
The FDA has approved ziconotide ( Prialt - Elan) intrathecal infusion for management of severe chronic pain in patients who are intolerant of or refractory to other treatments. Ziconotide is a synthetic neuronal N-type calcium channel blocker. It is intended for use with a programmable implanted microinfusion device, but an external microinfusion device can be used temporarily.
Issue 1214 · August 1, 2005 Free
In Brief: Palladone Withdrawn

The Medical Letter review of Palladone (hydromorphone HCl) extended-release capsules (March 14, 2005) warned that a lethal dose could be released if the new formulation was taken with alcohol. Because of that…

Med Lett Drugs Ther. 2005 Aug 1; 47(1214):61
The Medical Letter review of Palladone (hydromorphone HCl) extended-release capsules (March 14, 2005) warned that a lethal dose could be released if the new formulation was taken with alcohol. Because of that risk, the FDA asked the manufacturer (Purdue) to withdraw the drug from the market (FDA News. July 13, 2005; FDC Reports – “The Pink Sheet” July 18, 2005; 67:3) .
Issue 1204 · March 14, 2005
Palladone for Chronic Pain

A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride ( Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with…

Med Lett Drugs Ther. 2005 Mar 14; 47(1204):21-3
A once-daily extended-release (ER) oral formulation of the opioid analgesic hydromorphone hydrochloride ( Palladone - Purdue Pharma) has been approved by the FDA for treatment of opioid-tolerant patients with persistent moderate to severe pain. Hydromorphone HCl, a semisynthetic congener of morphine and active metabolite of hydrocodone that has been used since the 1920s, is also available in immediate-release oral, injectable and suppository forms ( Dilaudid , and others).
Issue 1188 · August 2, 2004
Trospium (Sanctura): Another Anticholinergic for Overactive Bladder

Trospium chloride ( Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available…

Med Lett Drugs Ther. 2004 Aug 2; 46(1188):63-4
Trospium chloride ( Sanctura - Indevus/Odyssey) has been approved by the FDA for treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. It has been available in Europe for many years.
Issue 23 · July 1, 2004
Drugs for Pain

Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of…

Treat Guidel Med Lett. 2004 Jul; 2(23):47-54
Three types of analgesic drugs are available: non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; opioids; and adjuvant drugs that are not usually thought of as analgesics, such as antidepressants, which can act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Combining two different types of analgesics may provide an additive analgesic effect without necessarily increasing adverse effects.
Issue 1141 · October 14, 2002
Generic drugs

When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the…

Med Lett Drugs Ther. 2002 Oct 14; 44(1141):89-90
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?
Issue 1113 · September 17, 2001
Oxycodone OxyContin

Recent reports of inappropriate use and diversion of OxyContin tablets have prompted Purdue Pharma to include a "Black Box Warning"in the product labeling to call attention to the potential for abuse and to…

Med Lett Drugs Ther. 2001 Sep 17; 43(1113):80-1
Recent reports of inappropriate use and diversion of OxyContin tablets have prompted Purdue Pharma to include a "Black Box Warning"in the product labeling to call attention to the potential for abuse and to reinforce the FDA-approved indication "...for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time..."
Issue 1085 · August 21, 2000
Drugs for Pain

Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought…

Med Lett Drugs Ther. 2000 Aug 21; 42(1085):73-8
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. Non-opioids can be given concurrently with opioids for an additive analgesic effect.
Issue 1033 · August 14, 1998
Drugs for Pain

Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, some drugs not usually…

Med Lett Drugs Ther. 1998 Aug 14; 40(1033):79-84
Three types of analgesic drugs are available: first, non-opioids, including aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, some drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain.
Issue 1022 · March 13, 1998
Trovafloxacin

Trovafloxacin ( Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial…

Med Lett Drugs Ther. 1998 Mar 13; 40(1022):30-1
Trovafloxacin ( Trovan - Pfizer) and its prodrug alatrofoxacin (Trovan IV) are new fluroroquinolones marketed for an unusually wide variety of infections, including oral and intravenous treatment of nosocomial and community-acquired pneumonia, acute ecerbations of chronic bronchitis, acute sinusitis, complicate intra-abdominal and pelvic infections, diabetic foot infection, uncomplicated urinary tract infection, prostatitis, cervicitis and uncomplicated gonorrhea.
Issue 960 · October 27, 1995
Nalmefene - Long-Acting Injectable Opioid Antagonist

Nalmefene ( Revex - Ohmeda), an i methylene analog of naltrexone ( Trexan ), is a long-acting opioid antagonist that has been approved by the US Food and Drug Administration for reversal of postoperative…

Med Lett Drugs Ther. 1995 Oct 27; 37(960):97-8
Nalmefene ( Revex - Ohmeda), an i methylene analog of naltrexone ( Trexan ), is a long-acting opioid antagonist that has been approved by the US Food and Drug Administration for reversal of postoperative opioid drug effects, including respiratory depression, sedation and hypotension and for management of known or suspected opioid overdose in the emergency department. The only other opioid antagonists available in the USA are naloxone ( Narcan ), which is also injectable but has a short duration of action, and naltrexone, which has a long duration of action but is marketed only for oral use.
Issue 887 · January 8, 1993
Drugs for Pain

Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as…

Med Lett Drugs Ther. 1993 Jan 8; 35(887):1-6
Three types of analgesic drugs are available in the USA: first, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen; second, opioids; and third, drugs not usually thought of as analgesics, which act as adjuvants when given with NSAIDs or opioids, or have analgesic activity of their own in some types of pain. (American Pain Society, Principles of analgesic Use , 3rd ed, Skokie, illinois: American pain society, 1992).
Issue 829 · October 19, 1990
Dezocine

Dezocine ( Dalgan - Astra), a new synthetic opioid agonist/antagonist structurally related to pentazocine ( Talwin ), was recently approved for parenteral use as an analgesic by the US Food and Drug…

Med Lett Drugs Ther. 1990 Oct 19; 32(829):95-6
Dezocine ( Dalgan - Astra), a new synthetic opioid agonist/antagonist structurally related to pentazocine ( Talwin ), was recently approved for parenteral use as an analgesic by the US Food and Drug Administration.
Issue 825 · August 24, 1990
Ketorolac Tromethamine

Ketorolac (kee'; toe role ak) tromethamine ( Toradol ), manufactured by Syntex but also marketed by Roche, is the first parenteral nonsteroidal anti-inflammatory drug (NSAID) to become available for analgesic…

Med Lett Drugs Ther. 1990 Aug 24; 32(825):79-80
Ketorolac (kee'; toe role ak) tromethamine ( Toradol ), manufactured by Syntex but also marketed by Roche, is the first parenteral nonsteroidal anti-inflammatory drug (NSAID) to become available for analgesic use in the USA. Parenteral indomethacin (Indocin I.V.) has been marketed here since 1985, but only for treatment of patent ductus arteriosus in newborn infants. Other parenteral NSAIDs are available in other parts of the world, but low potency, poor aqueous solubility, and substantial tissue irritation on injection have limited their usefulness. Ketorolac has been approved by the US Food and Drug Administration for intramuscular (IM) treatment of moderate to severe pain.
Issue 805 · November 17, 1989
Patient-Controlled Analgesia

Automated intravenous delivery systems have recently become commercially available for intermittent self-administration of analgesics. Patient-controlled analgesia (PCA) has been used effectively to relieve…

Med Lett Drugs Ther. 1989 Nov 17; 31(805):104
Automated intravenous delivery systems have recently become commercially available for intermittent self-administration of analgesics. Patient-controlled analgesia (PCA) has been used effectively to relieve after a wide variety of surgical procedures. It has also been effective for pain associated with labor, sickle cell crisis, and chronic pain caused by cancer.